Faron Pharmaceuticals Oy (LSE: FARN) is a clinical-stage biopharmaceutical company based in Finland, focused on immunotherapies for cancer and acute inflammatory conditions. Its lead candidate, bexmarilimab, is being developed to enhance immune response in solid tumours and sepsis. Faron leverages scientific innovation and clinical partnerships to advance novel treatments for serious diseases.
最新股票文章
為何麥可·貝瑞（Michael Burry）剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票，清空了他的整個投資組合，只保留一支股票，並對這家公司加碼，而其他投資人則紛紛出逃。
18:37, 22 7月 2025
評級和評論
評級和評論
